Efficacy and safety of atomoxetine in childhood attention-deficit/ hyperactivity disorder with comorbid oppositional defiant disorder

Journal of Attention Disorders

Volumn 8, Issue 2, 2004, Pages 45-52

  Kaplan, S ^b   Heiligenstein, J ^c   West, S ^a   Busner, J ^b   Harder, D ^c   Dittmann, R ^d   Casat, C ^e   Wernicke, J F ^c  

^a Clinical Neuroscience Solutions   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e CAROLINAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; CHILDHOOD DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SCHOOL CHILD; SCORING SYSTEM; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; VOMITING;

EID: 11444255970     PISSN: 10870547     EISSN: None     Source Type: Journal    
DOI: 10.1177/108705470400800202     Document Type: Article

References (24)

1. American Academy of Pediatrics (2000). Clinical practice guideline: Diagnosis and evaluation of the child with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 105, 1158-1170.
2. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th Ed. - Text Revision). Washington, DC: Author.
3. August, G. J., Realmuto, G. M., Joyce, T., & Hektner, J. M. (1999). Persistence and desistance of Oppositional Defiant Disorder in a community sample of children with ADHD. Journal of the American Academy of Child Psychiatry, 38, 1262-1270.
4. Bymaster, F. P., Katner, J., Nelson, D. L., Hemricke-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention-Deficit/Hyperactivity Disorder. Neuropsychopharmacology, 27, 699-711.
5. Comings, D. E., Gade-Andavolu, R., Gonzalez, N., Wu, S., Muhleman, D., Blake, H., et al. (2000). Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clinical Genetics, 58, 31-40.
6. Conners, C.K. (2000). Conners' Rating Scales-Revised (CRS-R). Toronto, Canada: Multi-Health Systems.
7. Dunne, J. E. (1999). Attention-Deficit/Hyperactivity Disorder and associated childhood disorders. Primary Care, 26, 349-372.
8. DuPaul, G. J., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford Press.
9. Goldman, L. S., Genel, M., Bezman, R. J., & Slanetz, P. J. (1998). Diagnosis and treatment of Attention-Deficit/ Hyperactivity Disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association, 279, 1100-1107.
10. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare.
11. Kaufman, J., Birmaher, B., Brent, D., Rao, U., & Ryan, N. (1996). Kiddie-SADS-Present and Lifetime Version (K-SADS-PL): The Department of Psychiatry, University of Pittsburgh School of Medicine.
12. Klein, R. G., Abikoff, H., Klass, E., Ganaeles, D., Seese, L. M., & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder with and without Attention Deficit Hyperactivity Disorder. Archives of General Psychiatry, 54, 1073-1080.
13. Kratochvil, C. (2003, May). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Paper presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA.
14. Kuhne, M., Schachar, R., & Tannock, R. (1997). Impact of comorbid oppositional or conduct problems on Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1715-1725.
15. Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
16. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., et al. (2001). Atomoxetine in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, e83.
17. MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/ hyperactivity disorder. The MTA Group. Multimodal Treatment Study of Children with ADHD, Archives of General Psychiatry, 56, 1073-1086.
18. Newcorn, J. H., Halperin, J. M., Jensen, P. S., Abikoff, H. B., Arnold, L. E., Cantwell, D. P., et al. (2001). Symptom profiles in children with ADHD: Effects of comorbidity and gender. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 137-146.
19. Popper, C. W. (2000). Pharmacological alternatives to psychostimulants for the treatment of Attention-Deficit/ Hyperactivity Disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 605-646.
20. Reich, W., Welner, Z, & Herjanic, B. (1997). Diagnostic Interview for Children and Adolescents -IV (DICA-IV). Toronto, Canada: Multi-Health Systems.
21. Spencer, T., Biederman, J., Heiligenstein, J., Wilens, T., Faries, D., Prince, J., et al. (2001). An open-label, dose-ranging study of atomoxetine in children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 11, 251-265.
22. Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., et al. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
23. Wechsler, D. (1991). Wechsler Intelligence Scale for Children (WISC-III). San Antonio, TX: The Psychological Corporation.
24. World Medical Association (2002). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Retrieved September 15, 2004 from http://www.wma.net/e/policy/pdf/17c.pdf.